PharmAthene Updates Status Of SparVax Anthrax Vaccine Contract

April 7, 2014 PharmAthene, Inc. announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax® anthrax vaccine contract through a partial termination for convenience.  BARDA will provide additional guidance to PharmAthene on the contractual changes, following which …

Anthrax vaccine showdown as PharmAthene’s SparVax Phase II gets FDA go ahead

PharmAthene have announced that the FDA has lifted the clinical hold previously placed on the Phase II study of it's next generation anthrax vaccine, SparVax. The FDA had originally placed a hold on the trial back in August 2012, requesting that PharmaAthene "provide additional stability data for both its engineering and GMP lots of U.S. manufactured Final Drug Product, as …